208 related articles for article (PubMed ID: 2913284)
1. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
[TBL] [Abstract][Full Text] [Related]
2. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
Worms P; Kan JP; Wermuth CG; Roncucci R; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):241-50. PubMed ID: 3100770
[TBL] [Abstract][Full Text] [Related]
3. Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.
Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():106-7. PubMed ID: 2248060
[TBL] [Abstract][Full Text] [Related]
4. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
Da Prada M; Keller HH; Kettler R
Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
[TBL] [Abstract][Full Text] [Related]
7. Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Da Prada M; Kettler R; Keller HH; Burkard WP; Muggli-Maniglio D; Haefely WE
J Pharmacol Exp Ther; 1989 Jan; 248(1):400-14. PubMed ID: 2783611
[TBL] [Abstract][Full Text] [Related]
8. Pre-clinical pharmacology of moclobemide. A review of published studies.
Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
[TBL] [Abstract][Full Text] [Related]
9. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant.
Colzi A; d'Agostini F; Cesura AM; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S17-20. PubMed ID: 1546133
[TBL] [Abstract][Full Text] [Related]
10. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.
Kettler R; Da Prada M; Burkard WP
Acta Psychiatr Scand Suppl; 1990; 360():101-2. PubMed ID: 2248058
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of moclobemide.
Haefely W; Burkard WP; Cesura A; Colzi A; Kettler R; Lorez HP; Martin JR; Moreau JL; Richards JG; Schaffner R
Clin Neuropharmacol; 1993; 16 Suppl 2():S8-18. PubMed ID: 8313402
[TBL] [Abstract][Full Text] [Related]
13. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
14. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
15. Some basic aspects of reversible inhibitors of monoamine oxidase-A.
Da Prada M; Kettler R; Burkard WP; Lorez HP; Haefely W
Acta Psychiatr Scand Suppl; 1990; 360():7-12. PubMed ID: 2248079
[TBL] [Abstract][Full Text] [Related]
16. Interaction of moclobemide and tricyclic antidepressants with the tyramine pressor effect in rats.
Burkard W; d'Agostini F; Kettler R; Da Prada M
Psychopharmacology (Berl); 1992; 106 Suppl():S35-6. PubMed ID: 1546137
[TBL] [Abstract][Full Text] [Related]
17. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition.
Kan JP; Steinberg R; Mouget-Goniot C; Worms P; Bizière K
J Pharmacol Exp Ther; 1987 Jan; 240(1):251-8. PubMed ID: 3100771
[TBL] [Abstract][Full Text] [Related]
18. [The comparative influence of pyrazidol, inkazan and other antidepressant monoamine oxidase inhibitors on the pressor effect of tyramine].
Andreeva NI; Golovina SM; Faermark MF; Shvarts GIa; Mashkovskiĭ MD
Farmakol Toksikol; 1991; 54(2):38-40. PubMed ID: 1884793
[TBL] [Abstract][Full Text] [Related]
19. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Lavian G; Finberg JP; Youdim MB
Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
[TBL] [Abstract][Full Text] [Related]
20. Moclobemide. An update of its pharmacological properties and therapeutic use.
Fulton B; Benfield P
Drugs; 1996 Sep; 52(3):450-74. PubMed ID: 8875133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]